結論與建議

本研究之肌無力症患者自行報告之結果（Patient-Reported Outcome,PRO）：不 同焦慮程度是影響生活品質主要因子，焦慮分數越高，生活品質越差；在最年長 的樣本顯示，憂鬱會影響生活品質，但有擔任俱樂部幹部對生活品質有正向效果。

精神方面的疾病是肌無力症患者不容忽視的問題，在治療肌無力症的同時，

心理的健康也是醫療團隊應積極維護。肌無力俱樂部對提升生活品質的功能，在 年長的樣本中得到驗證，這一組人是擔任肌無力俱樂部幹部比例最高。幹部的主 要工作為主動積極關懷住院與特別門診病患，也會到患者家中進行探視，其培訓 內容除了教授關懷技巧，也包括心理健康課程，所以幹部在關懷病友的同時，對 於自我的心理健康也得到提升，進而促進其生活品質。可以多鼓勵所有病友參加 幹部的培訓課程，讓病友轉換生病者的角色，成為主動關懷的人，對於其生活品 質會有所助益。臨床上，建議患者全面進行肌無力症生活品質量表及焦慮憂鬱量 表調查，以追蹤患者生活品質及心理狀況，對於焦慮憂鬱患者能及早介入轉診治

在病友團體對患者生活品質的影響方面，研究對象可以設定從它院轉入的病 患，在其第一次就診時填寫生活品質問卷，待半年後追蹤有病友團體介入，其生 活品質差異狀況。也可以做跨院區調查，比較有無病友團體的組織，對患者生活 品質是否有差異。

有研究指出，有一些肌無力症患者常伴隨有睡眠障礙，特別是睡眠呼吸障礙 及阻塞性呼吸睡眠中止症，這些病症會影響睡眠品質進而影響生活品質²⁰；也有研 究顯示，類固醇用量會影響生活品質^{19, 22}，這些影響生活品質的因子在台灣的患者 未獲得驗證，未來可以結合更多的臨床資料，繼續研究與探討。

參考文獻

1.

曾旭民, 盧瑞芬, 蔡益堅. 國人生活品質評量 (Ⅱ): SF-36 台灣版的常模與 效度檢測. 臺灣公共衛生雜誌. 2003;22(6):512-518.

2.

Food and Drug Administration U. Guidance for Industry on Patient-Reported Outcome Measures:Use in Medical Product Development to Support Labeling Claims. 2009.

3.

Marshall S, Haywood K, Fitzpatrick R. Impact of patient‐reported outcome measures on routine practice: a structured review. Journal of evaluation in

clinical practice. 2006;12(5):559-568.

4.

陳玉黛, 蔡秀鸞, 林佩芬. 肌無力症病患疾病感受, 情緒與生活品質之相關 性探討. 護理雜誌. 2003;50(6):43-50.

5.

Paul RH, Nash JM, Cohen RA, Gilchrist JM, Goldstein JM. Quality of life and well‐being of patients with myasthenia gravis. Muscle & nerve.

2001;24(4):512-516.

6.

Padua L, Evoli A, Aprile I, et al. Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements. Neurological Sciences. 2001;22(5):363-369.

7.

Rostedt A, Padua L, Stålberg EV. Correlation between regional myasthenic weakness and mental aspects of quality of life. European journal of neurology.

2006;13(2):191-193.

8.

Raggi A, Leonardi M, Antozzi C, et al. Concordance between severity of disease, disability and health-related quality of life in Myasthenia gravis. Neurological

sciences. 2010;31(1):41-45.

9.

Leonardi M, Raggi A, Antozzi C, et al. The relationship between health,

disability and quality of life in Myasthenia Gravis: results from an Italian study.

Journal of neurology. 2010;257(1):98-102.

10.

Raggi A, Leonardi M, Mantegazza R, Casale S, Fioravanti G. Social support and self-efficacy in patients with Myasthenia Gravis: a common pathway towards positive health outcomes. Neurological sciences. 2010;31(2):231-235.

11.

Basta IZ, Pekmezović TD, Perić SZ, et al. Assessment of health-related quality of life in patients with myasthenia gravis in Belgrade (Serbia). Neurological

Sciences. 2012;33(6):1375-1381.

12.

Jaretzki A, Barohn RJ, Ernstoff RM, et al. Myasthenia gravis Recommendations for clinical research standards. Neurology. 2000;55(1):16-23.

13.

Padua L, Evoli A, Aprile I, et al. Myasthenia gravis outcome measure:

development and validation of a disease-specific self-administered questionnaire.

Neurological Sciences. 2002;23(2):59-68.

14.

Padua L, Galassi G, Ariatti A, et al. Myasthenia gravis self-administered questionnaire: development of regional domains. Neurological Sciences.

2005;25(6):331-336.

15.

Mullins LL, Carpentier MY, Paul RH, Sanders DB. Disease‐specific measure of quality of life for myasthenia gravis. Muscle & nerve. 2008;38(2):947-956.

16.

Burns TM, Conaway MR, Cutter GR, Sanders DB. Less is more, or almost as much: A 15‐item quality‐of‐life instrument for myasthenia gravis. Muscle &

17.

Mourao AM, Araujo CM, Barbosa LSM, et al. Brazilian cross-cultural translation and adaptation of the" Questionnaire of Life Quality Specific for Myasthenia Gravis-15 items". Arquivos de neuro-psiquiatria.

2013;71(12):955-958.

18.

Liu F-b, Chen X-l, Guo L, Liu X-b. Evaluation of a scale of patient-reported outcomes for the assessment of myasthenia gravis patients in China. Chinese

journal of integrative medicine. 2012;18:737-745.

19.

Masuda M, Utsugisawa K, Suzuki S, et al. The MG‐QOL15 Japanese version:

Validation and associations with clinical factors. Muscle & nerve.

2012;46(2):166-173.

20.

Martínez‐Lapiscina EH, Erro ME, Ayuso T, Jericó I. Myasthenia gravis: sleep quality, quality of life, and disease severity. Muscle & nerve.

2012;46(2):174-180.

21.

Maniaol A, Brunborg C, Tallaksen C. Development and validation of a self-administered questionnaire for myasthenia gravis patients.

Neuroepidemiology. 2010;34(4):253-261.

22.

Utsugisawa K, Suzuki S, Nagane Y, et al. Health‐Related Quality of Life and Treatment Targets in Myasthenia Gravis. Muscle & nerve. 2014.

23.

Kulaksizoglu IB. Mood and Anxiety Disorders in Patients with Myasthenia Gravis. CNS drugs. 2007;21(6):473-481.

24.

邱浩彰, 葉建宏. 神經科: 肌無力症在台灣的臨床觀察與治療原則. 臺灣醫 學. 1997;1(5):658-662.

25.

Burns TM. History of outcome measures for myasthenia gravis. Muscle & nerve.

2010;42(1):5-13.

26.

MANTEGAZZA R, BAGGI F, ANTOZZI C, et al. Myasthenia gravis (MG):

epidemiological data and prognostic factors. Annals of the New York Academy of

Sciences. 2003;998(1):413-423.

27.

PHILLIPS LH. The epidemiology of myasthenia gravis. Annals of the New York

Academy of Sciences. 2003;998(1):407-412.

28.

Black N. Patient reported outcome measures could help transform healthcare.

BMJ. 2013;346:f167.

29.

Cappelleri JC, Zou KH, Bushmakin AG, Alvir JMJ, Alemayehu D, Symonds T.

Patient-Reported Outcomes. Measurement,Implementation and Interpretation.

2014.

30.

薛亞聖. 建構台灣地區永續性生活品質指標評量系統-醫療品質指標之建立 (I). 2002.

31.

盧瑞芬, 曾旭民, 蔡益堅. 國人生活品質評量 (Ⅰ): SF-36 台灣版的發展及 心理計量特質分析. 臺灣公共衛生雜誌. 2003;22(6):501-511.

32.

Rostedt A, Padua L, Stålberg E. Validation of the Swedish version of the disease-specific Myasthenia Gravis Questionnaire. Neurological Sciences.

2006;27(2):91-96.

33.

Basta I, Pekmezović T, Padua L, et al. Validation of Serbian version of the disease‐specific myasthenia gravis questionnaire. Acta Neurologica

Scandinavica. 2010;122(2):110-114.

34.

Rostedt A, Padua L, Stålberg EV. Correlation between a patient-derived functional questionnaire and abnormal neuromuscular transmission in

Myasthenia Gravis patients. Clinical neurophysiology. 2005;116(9):2058-2064.

35.

Paul RH, Cohen RA, Goldstein JM, Gilchrist JM. Fatigue and its impact on

patients with myasthenia gravis. Muscle & nerve. 2000;23(9):1402-1406.

36.

Emery EJ, Szymanski HV. Psychological symptoms preceding diagnosed myasthenia gravis. Psychosomatics. 1981;22(11):993-995.

37.

Rohr W. [Myasthenia gravis in the frontier of psychiatric diagnosis].

Psychiatrische Praxis. 1992;19(5):157-163.

38.

Ybarra MI, Kummer A, Frota ERC, Oliveira JTd, Gomez RS, Teixeira AL.

Psychiatric disorders in myasthenia gravis. Arquivos de neuro-psiquiatria.

2011;69(2A):176-179.

39.

Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta

psychiatrica scandinavica. 1983;67(6):361-370.

40.

劉棻, 劉雪娥. 截肢病患支持團體的發展與設計. 高雄護理雜誌.

2011;28(3):31-41.

41.

Halm M. Strategies for developing a family support group. Focus on critical

care/American Association of Critical-Care Nurses. 1991;18(6):444-455,

458-449.

42.

Cain EN, Kohorn EI, Quinlan DM, Latimer K, Schwartz PE. Psychosocial benefits of a cancer support group. Cancer. 1986;57(1):183-189.

43.

Burns TM, Grouse C, Conaway MR, Sanders DB. Construct and concurrent validation of the MG‐QOL15 in the practice setting. Muscle & nerve.

2010;41(2):219-226.

44.

Burns TM, Grouse C, Wolfe GI, Conaway MR, Sanders DB. The MG‐QOL15 for following the health‐related quality of life of patients with myasthenia gravis.

Muscle & nerve. 2011;43(1):14-18.

在文檔中 肌無力症患者生活品質與焦慮憂鬱之相關因素 (頁 72-77)